{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-134759","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.464632+00:00","generated_at":"2026-05-29T05:13:53.765691+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Olema gets FDA IND clearance for OP-3136; palazestrant combo shows 73% 6-month PFS","bullets":["FDA cleared IND for KAT6 inhibitor OP-3136; Phase 1 to start early 2025.","Phase 1b/2 palazestrant + ribociclib: median PFS not reached at 12-month follow-up.","6-month PFS rate 73% overall, 81% in ESR1 mutant patients, 68% after prior CDK4/6i.","ORR 27% (10/37) in measurable disease; 76% CBR overall.","Combination well tolerated with no new safety signals; plans for Phase 3 OPERA-02 in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-134759","json":"https://secwatch.observer/filing/0000950170-24-134759.json","markdown":"https://secwatch.observer/filing/0000950170-24-134759.md","text":"https://secwatch.observer/filing/0000950170-24-134759.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024134759/0000950170-24-134759-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024134759/olma-20241209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:13:53.765691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}